Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEOGENOMICS INC Director's Dealing 2022

Mar 4, 2022

32227_dirs_2022-03-03_382f1117-775b-42b4-a74b-cdd405b47f52.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-03-01

Reporting Person: Wallar Gina M (President, Pharma Services)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-03-01 Common Stock A 11677 Acquired 33443 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-03-01 Stock Option (Right to Buy) $21.41 A 28506 Acquired 2029-03-01 Common Stock (28506.0) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $9.22 2023-04-19 Common Stock (6667.0) 6667 Direct
Stock Option (Right to Buy) $13.87 2023-12-12 Common Stock (8334.0) 8334 Direct
Stock Option (Right to Buy) $20.83 2026-05-01 Common Stock (7153.0) 7153 Direct
Stock Option (Right to Buy) $27.34 2027-05-01 Common Stock (7879.0) 7879 Direct
Stock Option (Right to Buy) $48.99 2028-05-01 Common Stock (8595.0) 8595 Direct
Stock Option (Right to Buy) $43.95 2028-07-05 Common Stock (10126.0) 10126 Direct

Footnotes

F1: On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.

F2: This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3.

F3: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.

F4: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.

F5: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F6: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F7: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F8: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F9: On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date.